Further studies are clearly needed to understand the mechanism of pathological TDP-43 and the ambiguous role of lipocalin-2 in ALS and FTD pathogenesis and its potential as a therapeutic target or biomarker for assessing neuroinflammation. This evidence concerns the gene LCN2 and amyotrophic lateral sclerosis.